Lantheus Medical Imaging     Print Page  Close Window

2017 Press Releases

Keyword Search
2017 | 2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
04/25/17Lantheus and GE Healthcare Announce the Signing of a Definitive License Agreement for Worldwide Development and Commercialization of Flurpiridaz F 18
Companies also announce the extension and expansion of their existing commercial supply agreement for nuclear products through 2020 NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Apr. 25, 2017-- Lantheus Holdings, Inc. (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. (collectively, “Lantheus”), and GE Healthcare (NYSE:GE), today announced the signing of a definitive license agreement (the “definitive agreement”) for the continued Pha... 
04/18/17Lantheus Holdings to Host First Quarter 2017 Earnings Conference Call on May 2, 2017 at 4:30 p.m. Eastern Time
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Apr. 18, 2017-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call at 4:30 p.m. ET on Tuesday, May 2, 2017, to discuss its financial and operating results for the first quarter of 2017. To access the live conference call via telephone, please dial 1-866-498-8390 (U.S. callers) or 1-678-509-7599 (international callers) and provide passcod... 
03/30/17Lantheus Announces Refinancing of its Debt Facility
Increases available liquidity; positive impact on cash flow projected to be approximately $5 million per year NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Mar. 30, 2017-- Lantheus Holdings, Inc. (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. (collectively, “Lantheus” or “the Company”), today announced the closing of a new $275 million term loan facility (the “new term loan”) and a new $75 million five-year cash-flow revolver ... 
03/13/17Lantheus Holdings, Inc. Announces Public Secondary Offering of 3,000,000 Shares of Common Stock by Selling Stockholders
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Mar. 13, 2017-- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ:LNTH), today announced an agreement to sell 3,000,000 shares of its common stock to be offered by certain of its existing stockholders (the “Selling Stockholders”), pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the “SEC”) on Form S-3. The Company will not receive any proceeds fro... 
02/21/17Lantheus Holdings, Inc. Reports 2016 Fourth Quarter and Full Year Financial Results; Provides 2017 Guidance
Company exceeds full year 2016 guidance, posts revenue of $301.9 million, net income of $26.8 million and Adjusted EBITDA of $78.3 million NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Feb. 21, 2017-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today... 
02/21/17Lantheus Holdings and GE Healthcare Announce the Signing of a Term Sheet for Worldwide Development and Commercialization of Flurpiridaz F 18
NORTH BILLERICA, Mass. & CHALFONT ST GILES, United Kingdom--(BUSINESS WIRE)--Feb. 21, 2017-- Lantheus Medical Imaging, Inc. (“LMI”), a subsidiary of Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), and GE Healthcare (NYSE:GE), today announced the signing of a term sheet relating to the continued Phase III development and worldwide commercialization of flurpiridaz F 18, an investigational positron emission tomography (PET) myocardial perfus... 
02/07/17Lantheus Holdings to Host Fourth Quarter and Full Year 2016 Earnings Conference Call and Provide 2017 Guidance on February 21, 2017 at 4:30 p.m. Eastern Time
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Feb. 7, 2017-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call at 4:30 p.m. ET on Tuesday, February 21, 2017, to discuss its financial and operating results for the fourth quarter and full year of 2016. The Company will also provide guidance for 2017. To access the live conference call via telephone, please dial 1-866-498-8390 (U.S. c... 
02/02/17Lantheus Medical Imaging Announces FDA Approval of DEFINITY® Label Update
Label Revision Removes Cardiac Shunt Contraindication NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Feb. 2, 2017-- Lantheus Medical Imaging, Inc. ("Lantheus") today announced U.S. Food and Drug Administration (FDA) approval of an important label update for DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension which removes the contraindication statement related to use in patients with a known or suspected cardiac shunt from the U.S. Prescrib... 
01/26/17Lantheus Holdings Appoints New Member to its Board of Directors
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Jan. 26, 2017-- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced the appointment of Julie McHugh as a member of its Board of Directors, effective January 25, 2017. The Company's Board of Directors n...